SpectraCure AB has started clinical trials of treatment of prostate cancer. SpectraCure cooperates with Kitron AB in the fields of development and manufacturing of the equipment.
The medical technology company SpectraCure AB in Lund, Sweden is developing a method for treatment of solid tumours inside the human body, using photodynamic therapy. The project now enters a phase with clinical trials, and the first patients have been treated at the University Hospital of Malmö.
The cooperation with Kitron consists of further development of hardware and software and manufacturing of instruments for the coming clinical trials. Next step is to adapt the instruments for future serial production.
"We have chosen Kitron because Kitron has extensive experience of medical technology companies and competence within the field of adopting this kind of products for serial production" says Kerstin Jakobsson, Managing Director of SpectraCure.
"SpectraCure has a product and a method with an interesting potential with reduced cost of treatment and opening new possibilities in cancer therapy" says Johan Sandstedt, Business Development Manager for medical technology in Kitron AB. "We are of course happy and proud that SpectraCure has chosen us. It is a customer with high demands and expectations of our technical competence".
7 December 2007
Kitron ASA
For further information, please contact:
Johan Sandstedt, Business Development Manager for medical technology in Kitron AB, phone: (+46) 736 68 33 21, or e-mail: johan.sandstedt@kitron.com
Kitron is one of Scandinavia's leading companies in development, industrialisation and production of electronics for the data/telecom, defence/marine, medical, automotive and other industries. The company is located in Norway, Sweden and Lithuania. Kitron had a revenue of about NOK 1.7 billion in 2006 and has about 1,300 employees.
See also www.kitron.com.
SpectraCure AB is a Swedish medical technology company which aims to to commercialize the company's technical product program in the field of photo dynamic therapy for treatment of different types of cancer. The method and technology is based on research done at the University Hospital in Lund, Sweden by professor Sune Svanberg and collegues.
www.spectracure.se